Arbutus Biopharma Corporation (NASDAQ:ABUS)‘s stock had its “buy” rating restated by Chardan Capital in a research report issued to clients and investors on Monday.

ABUS has been the subject of several other reports. Zacks Investment Research lowered Arbutus Biopharma Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Ladenburg Thalmann Financial Services began coverage on Arbutus Biopharma Corporation in a research note on Friday, June 2nd. They set a “buy” rating and a $32.00 price objective for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Arbutus Biopharma Corporation has an average rating of “Buy” and a consensus price target of $11.65.

Arbutus Biopharma Corporation (NASDAQ:ABUS) opened at 3.45 on Monday. Arbutus Biopharma Corporation has a 52 week low of $2.35 and a 52 week high of $4.49. The company’s 50-day moving average price is $3.67 and its 200-day moving average price is $3.22. The company’s market capitalization is $189.83 million.

Arbutus Biopharma Corporation (NASDAQ:ABUS) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.04. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $7.50 million. Equities analysts forecast that Arbutus Biopharma Corporation will post ($1.46) earnings per share for the current fiscal year.

WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at

An institutional investor recently raised its position in Arbutus Biopharma Corporation stock. Renaissance Technologies LLC boosted its stake in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 785.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 124,573 shares of the biopharmaceutical company’s stock after buying an additional 110,499 shares during the period. Renaissance Technologies LLC’s holdings in Arbutus Biopharma Corporation were worth $405,000 as of its most recent filing with the SEC. 66.53% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Corporation Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma Corporation (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with's FREE daily email newsletter.